Combining MER with AFP, tumor size, and BCLC resulted in improved sensitivity and specificity values of 85.7%/72.7%, 81.0%/89.5%, and 81.0%/94.4%, respectively (Table 2). The gene discussed is AFP; the disease is neoplasm.